Shots:

• The P-II/III DIAN-TU study involves assessing of solanezumab (400mg/q4w as initial dose and increased to ~25% of the total doses being administered @1600mg) vs PBO in patients with at risk for or with dominantly inherited Alzheimer's disease- caused by rare gene mutations  
• The P-II/III DIAN-TU study resulted in not meeting its 1EPs with its analysis for 2EPs are ongoing by Washington University and Lilly. The negative results do not impact ongoing A4 study of solanezumab
• Solanezumab is an investigational anti-amyloid mAb- currently being evaluated in preclinical Alzheimer's disease in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study

Click here ­to­ read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly